Innovative drug delivery strategies for topical photodynamic therapy using porphyrin precursors

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 26, Issue 2, 2007, Pages 105-116

  Morrow, Desmond I J ^a   Garland, Martin J ^a   McCarron, Paul A ^a   Woolfson, A David ^a   Donnelly, Ryan F ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Drug delivery; Photodynamic therapy; Stability; Topical application

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ALPHA TOCOPHEROL; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID DECYL ESTER; AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID METHYL ESTER; AMINOLEVULINIC ACID OCTYL ESTER; CLONIDINE; CYCLOSPORIN; ESTRADIOL; EUDRAGIT; FENTANYL; GLYCERYL TRINITRATE; HEMOGLOBIN; INSULIN; LIDOCAINE; NICOTINE; OXYBUTYNIN; PORPHYRIN DERIVATIVE; SALBUTAMOL; SCOPOLAMINE; TESTOSTERONE; UNCLASSIFIED DRUG; UNGUENTUM M;

ANALYTIC METHOD; BARRETT ESOPHAGUS; CONFERENCE PAPER; DISSOLUTION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; FREEZE DRYING; HUMAN; IONTOPHORESIS; LICHEN SCLEROSUS ET ATROPHICUS; MOTION SICKNESS; NONHUMAN; OINTMENT; ONYCHOMYCOSIS; PAGET BONE DISEASE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; STRATUM CORNEUM; TRANSDERMAL PATCH; VULVA CANCER;

EID: 34548078710     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.v26.i2.50     Document Type: Conference Paper

References (89)

1. Raab, O. Uber die Wirking fluoreszierender Stoffe auf Infusorien. Z.Bio.l 1900;39:524-46.
2. Von Tappeiner, H. Uber die Wirkung fluoreszierender Stoffe auf Infusorien nach Versuchen von O.Raab. Muench. Med. Wochenschr. 1900;-47:5-7.
3. Donnelly RF, McCarron PA, Woolfson AD. Drug delivery of aminolevulinic acid from topical formulations intended for photodynamic therapy. Photochem Photobiol. 2005;81:750-67.
4. De Rosa FS, Bently M. Photodynamic Therapy of skin cancers: sensitizers, clinical studies and future directives. Pharmaceut Res. 2000;17; 447-55.
5. Fonseca Vianna Lopez R, Lange N, Guy R, Bently M. Photodynamic therapy of skin cancer: Controlled drug delivery of 5-ALA and its esters. Adv Drug Deliv Rev. 2004;56:77-94.
6. Dougherty TJ. Photoradiation Therapy for cutaneous and subcutaneous malignancies. Investigat Dermatol. 1981;77:122-4.
7. Malik Z, Lugaci H. Destruction of erythroleukaemic cells by photoinactivation of endogenous porphyrins. Cancer. 1987;56:589-95.
8. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. Photochem Photobiol B. 1990;6:143-8.
9. Ackroyd R, Kelty C, Brown N, Reed M. The history of photodetection and photodynamic therapy. Photochem Photobiol. 2001;74(5):656-69.
10. Meijinders PJN, Star WM, De Bruijn RS, Treurniet-Donker AD, Van Mierlo MJM, Wijthoff SJM, Naafs B, Beerman H, Levendag PC. Clinical results of photodynamic therapy for superficial skin malignancies or actinic keratosis using topical 5-aminolevulinic acid. Lasers. 1996;11:123-31.
11. Kennedy JCS, Marcus SL, Pottier RH. Photodynamic therapy and photodiagnosis using endogenous photosensitisation induced by ALA: mechanisms and clinical results. Clin Laser. 1996;14:289-304.
12. Pottier RH, Chow YFA, La Plante JP; Truscott TG, Kennedy JC, Beiner LA. Non-invasive technique for obtaining fluorescence excitation and emission spectra in vivo. Photochem Photobiol. 1986;44:679-87.
13. Loh CS, Vernon DI, MacRobert AJ, Bedwell J, Bown SG, Brown SB. Endogenous porphyrin distribution induced by 5-aminolevulinic acid in the tissue layers of the gastrointestinal tract. Photochem Photobiol B: Biol. 1993;20:47-54.
14. Wyld L, Burn JL, Reed MW, Brown NJ. Factors affecting aminolevulinic acid induced generation of protoporphyrin IX. Cancer. 1997;76:705-12.
15. Ackroyd R, Brown NJ, Davis MF, Stephenson TJ, Marcus SL, Stoddard CJ, Johnson AG, Reed MWR. Photodynamic therapy for dysplastic barret's oesophagus: a prospective double blind randomised placebo controlled trial. Gut. 2000;-47:612-5.
16. Leibovici L, Schoenfeld N, Yehoshua HA, Mamet R, Rakowsky E, Shindel A, Atsmon A. Activity of porphobilinogen deaminase in peripheral blood mononuclear cells of patients with metastatic cancer. Cancer. 1988;62:2297-300.
17. Navone NM, Polo CF, Frisardi AL, Andrade NE, Battle AM. Heme biosynthesis in human breast cancer-mimetic in vitro studies and some enzymatic activity levels. Int J Biochem. 1990;22:1407-11.
18. El-Sharabasy MMH, El-Waseef AM, Hafez MM, Salim SA. Porphyrin metabolism in some malignant diseases. Br J Cancer. 1992;65:409-12.
19. Dailey HA, Smith A. Differential interaction of porphyrins used in photoradiation therapy with ferrochelatase. Biochemistry. 1984;223:441-5.
20. Cairnduff F, Stringer MR, Hudson EJ, Ash DV, Brown SB. Superficial photodynamic therapy with topical 5-aminolevulinic acid for superficial primary and secondary cancer. Br J Cancer. 1994;-69:605-8.
21. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical 5-aminolevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. Photochem Photobiol B: Biol. 1995;29:53-7.
22. Soler AM, Warloe T, Tausjo J, Berner A. Photodynamic therapy by topical aminolevulinic acid, dimethyl sulfoxide and curettage in nodular basal cell carcinoma: a one year follow up study. Dermatol Venereol. 1999;79:204-6.
23. Meijnders PJN, Star WM, De Bruijn RS, Treurniet-Donker AD, Van Mierlo MJM, Wijthoff SJM, Naafs B, Beerman H, Levendag PC. Clinical results of photodynamic therapy of superficial skin malignancies or actinic keratosis using topical 5-aminolevulinic acid. Lasers. 1996;11:123-31.
24. Dijkstra AT, Majoie ML, Van Dongen JWF, Van weelden H, Van Vioten WA. Photodynamic therapy with violet light and topical 5-aminolevulinic acid in the treatment of actinic keratosis, Bowen's disease and basal cell carcinoma. J Eur Acad Dermatol Venereol. 2001;15:550-4.
25. Jeffes EW, McCullough JL, Weinstein GP, Fergin PE, Nelson JS, Shull TF, Simpson KR, Bukaty LM, Hoffman WL, Fong NL. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid: a pilot dose ranging study. Arch Dermatol. 1997;133:727-32.
26. Svanberg K, Andersson T, Killander D, Wang D, Stenarm U, Andersson-Engels S, Berg R, Johansson J, Svanberg S. Photodynamic therapy of nonmelanoma malignant tumours of the skin using topical 5-aminolevulinic acid sensitization and laser irradiation. Br J Dermatol. 1994;130:743-51.
27. Morton CA, Whitehurst C, Moseley H, McColl JH, Moore JV, Mackie RM. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol. 1996;135:766-71.
28. Morton CA, Whitehurst C, Moore JV, MacKie RM. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol. 2000;143:767-72.
29. Fehr MK, Hornung R, Schwarz VA, Simeon R, Haller U, Wyss P. Photodynamic therapy of vulvar intraeptihelial neoplasia iii using topically applied 5-aminolevulinic acid. Gyn.Oncol. 2001;80:62-6.
30. Martin -Hirsch PL, Whitehurst C, Buckley CH, Moore JV, Kitchener HC. Photodynamic treatment for lower genital tract intraepithelial neoplasia. Arch Dermatol. 1998;134:247-9.
31. Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, Stern PL, Moore JV, Corbitt G, Kitchener HC, Hampson LN. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res. 2001;61:192-6.
32. Zawislak A, Mc Carron PA, McCluggage WG, Price JH, Donnelly RF, McClelland RH, Dobbs SP, Woolfson AD. Successful photodynamic therapy of vulval Paget's disease using a novel patch based delivery system containing 5-aminolevulinic acid. Br J Obstet Gynacol. 2004;111:1-3.
33. Wierrani F, Kubin A, Jindra R, Henry M, Gharehbaghi K, Grin W, Soltz-Szotz J, Alth G, Grunberger W. 5-Aminolevulinic acid mediated photodynamic therapy of intraepithelial neoplasia and human papillomavirus of the uterine cervix - a new experimental approach. Cancer Detect Preview. 1999;23:351-5.
34. Hurlimann AF, Hanggi G, Panizzon RG. Photodynamic therapy of superficial basal cell carcinoma using topical 5-aminolevulinic acid in a nanocolloid lotion. Dermatology. 1998;197:248-54.
35. Dougherty TJ, Gormer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy. J Nat Cancer Inst. 1998;-90:889-905.
36. Konan YN, Gurny R, Allemann E. State of the art in the delivery of photosensitisers for photodynamic therapy. Photochem Photobiol B: Biol. 2002;66:89-106.
37. Lieb S, Szeimies RM, Lee G. Self adesive thin films for topical delivery of 5-aminolevulinic acid. Eur J Pharmaceut Biopharmaceut. 2002;53:99-106.
38. Casas A, Fukuda G, Di Venosa G, Del AM, Batlle C. The influence of the vehicle on the synthesis of porphyrins after topical application of 5-aminolevulinic acid implications in cutaneous photodynamic sensitisation. Br J Dermatol. 2000;-143:564-72.
39. Malik Z, Kostenich G, Roitman L, Ehrenberg B, Orenstein A. Topical application of 5-aminolevulinic acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumours of mice. Photochem Photobiol B: Biol. 1995;28:213-8.
40. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M. Giercksky KE, Nesland JM. 5-aminolevulinic acid-based photodynamic therapy: clinical research and future challenges. Cancer. 1997;79:2282-308.
41. Morton CA, MacKie RM, Whitehurst C, Moore JV, McColl JH. Photodynamic therapy for basal cell carcinoma: effect of tumour thickness and duration of photosensitizer application on response. Arch Dermatol. 1998;134:248-49.
42. Donnelly RF, McCarron PA, Woolfson AD. Drug delivery of aminolevulinic acid from topical formulations intended for photodynamic therapy. Photochem Photobiol. 2005;81:750-67.
43. Brown L, Langer R. Transdermal delivery of drugs. Ann Rev Med. 1988;39:221-9.
44. Meidan VM, Michniak BB. Emerging technologies in transdermal therapeutics. Am J Therapeut. 2004;11:312-6.
45. Bretschko E, Szeimies RM, Landthaler M, Lee G. Topical 5-Aminolevulinic acid for photodynamic therapy of basal cell carcinoma. evaluation of stratum corneum permeability in vitro. J Cont Rel. 1996;42:203-8.
46. Pons P, Roald P, Nestor B, Rafael G, Agustin A. Transdermic patches for photodynamic therpapy of superficial lesions. Proceedings of 29th Annual Meeting of the American Society of Photobiology; 2001 July 7-12; Chicago. IL; Photobiology Online, Paper No. 123.
47. Valenta C, Auner BG, Loibl I. Skin Permeation and stability of 5-aminolevulinic acid in a new gel and patch preparation. J Cont Rel. 2005;107:495-501.
48. McCarron PA, Donnelly RF, Woolfson AD Zawislak A. Photodynamic therapy of vulval intraepithelial neoplasia using bioadhesive patch-based delivery of aminolevulinic acid. Drug Del Sys Sci. 2003;3:59-64.
49. Anders R, Merkle HP. Evaluation of laminated mucoadhesive patches for buccal drug delivery. Int J Pharm. 1989;49:231-40.
50. McCarron PA, Donnelly RF, Gilmore BF, Woolfson AD, McClelland R, Zawislak A, Price JH. Phototoxicity of 5-aminolevulinic acid in the hela cell line as an indicative measure of photodynamic effect after topical administration to gynaecological lesions of intraepithelial form. Pharm Res. 2004;21:1873-81.
51. McCarron PA, Donnelly RF, Woolfson AD, Zawislak A, Price JH, Maxwell P. Photodynamic treatment of lichen sclerosus and squamous hyperplasia using sustained topical delivery of aminolevulinic acid from a novel bioadhesive. Br J Dermatol. 2004;151:(Suppl 68),105-6.
52. Donnelly RF, McCarron PA, Ma LW, Juzenas P, Iani V, Woolfson AD, Zawislak AA, Moan J. Facilitated delivery of ALA to inaccessible regions via bioadhesive patch systems. J Environ Pathol Toxicol Oncol. 2006;25:1-14.
53. McCarron PA, Donnelly RF, Zawislak A, Woolfson AD, Price JH, McClelland R. Evaluation of a water-soluble bioadhesive patch for photodynamic therapy of vulval lesions. Int J Pharm. 2005;293:11-23.
54. Donnelly RF, Ma LW, Juzenes P, Iani V, McCarron PA, Woolfson AD, Moan J. Topical bioadhesive patch systems enhance selectivity of protoporphyrin IX accumulation. Photochem Photobiol. 2006;82:670-5.
55. Gilmore BF, McCarron PA, Morrow DIJ, Murphy DJ, Woolfson AD, Donnelly RF. In vitro phototoxicity of 5-aminolevulinic acid and its methyl ester and the influence of barrier properties on their release from a bioadhesive patch. Eur J Pharm Biopharm. 2006;63(3):295-309.
56. Donnelly RF, Juzenes P, McCarron PA, Ma LW, Woolfson AD, Moan J. Influence of formulation factors on methyl-ALA-induced protoporphyrin IX accumulation in vivo. Photodiag Photodyn Therapy. 2006;3:190-201
57. Donnelly RF, McCarron PA, Lightowler JM, Woolfson AD. Bioadhesive patch-based delivery of 5-aminolevulinic acid to the nail for photodynamic therapy of onychomycosis. J Control Rel. 2005;103:381-92.
58. Vornax V, Eleouet S, Carre J, Ioss P, Gouyette A, Leray AM, Merle C, Lajat Y, Patrice T. Potential efficacy of a delta 5-ALA bioadhesive gel formulation for the photodynamic treatment of lesions of the gastrointestinal tract in mice. J Pharm Pharmacol. 1997;49:652-6.
59. Bourre L, Thibaut S, Briffaud A, Lajat Y, Patrice T. Potential efficacy of a delta 5-ALA thermosetting gel formulation for use in photodynamic therapy of lesions of the gastrointestinal tract. Pharmaco Res. 2002:45:159-165.
60. Shah JC, Sadhale Y, Chilukuri Murthy D. Cubic phase gels as drug delivery systems. Adv Drug Del Rev. 2001;47:229-50.
61. Bender J, Ericson MB, Merclin N, Iani V, Rosen A, Engstrom, Moan J. Lipid cubic phases for improved topical drug delivery in photodynamic therapy. J Control Rel. 2005;106:350-60.
62. Turchiello RF, Vena FCB, Maillard Ph, Souza CS, Bentley MVBL, Tedesco AC. Cubic phase gel as drug delivery system for topical application of 5-ALA, its ester derivatives and m-THPC in photodynamic therapy (PDT). J Photochem Photobio B. 2003;70:1-6.
63. Wyatt D, Dorschel D. A cubic phase delivery system composed if glycerol monooleate and water for sustained release of water soluble drugs. Pharm Technol. 1992;10:116-30.
64. Lesile SB, Puvvada S, Ratna BR, Rudolph AS. Encapsulation of haemoglobin in a bicontinuous cubic phase lipid. Biochim Biophys Acta. 1996;2:-246-54.
65. Sadhale Y, Shah JC. Stabilization of insulin against agitation induced aggregation by the GMO cubic phase gel. Int J Pharm. 1999;1:51-64.
66. Sadhale Y, Sgag JC. Biological activity of insulin in gmo gels and the effect of agitation. Int J Pharm. 1999;191(1):65-74.
67. Lopes LB, Lopes JLC, Oliveira DCR, Thomazini JA, Garcia MTJ, Fantini MCA, Collett JH, Bentley MVLB. Liquid crystalline phases of monoolein and water for topical delivery of cyclosporin A: characterization and study of in vitro and in vivo delivery. Eur J Pharm Biopharm. 2006;63:146-155.
68. Carr MG, Corish J, Corrigan OI. Drug delivery from a liquid crystalline base across visking and human stratum corneum. Int J Pharm. 1997;157:-35-42.
69. Helledi LS, Schubert L. Release kinetics of acyclovir from a suspension of acyclovir incorporated in a cubic phase delivery system. Drug Dev Ind Pharm. 2001;27:1073-81.
70. Lofroth JE, Andreasson A, Rehmberg G. Liquid crystalline phases as drug delivery systems for drugs. II: in vitro, Proceedings of 15th International Symposium on Controlled Release of Bioactive Materials; Lincolnshire, IL. Controlled Release Society: St. Paul, MN; 1988. p. 380-1.
71. Alfons K, Engstrom S. Drug compatibility with the sponge phases formed in monoolein, water, and propylene glycol or poly(ethylene glycol). J Pharm Sci. 1998;87:1527-30.
72. Merclin N, Bender J, Sparr E, Guy RH, Ehrsson H, Engstrom S. Transdermal delivery from a lipid sponge phase - ionotophoretic and passive trans-port in vitro of 5-aminolevulinic acid and its methyl ester. J Control Rel. 2004;100:191-8.
73. Engstrom S. Drug delivery from cubic and other lipid-water phases. Lipid Technol. 1990;2:42-5.
74. 3) phase. Colloids Surf A: Physicochem Eng Asp. 2003;228:17-24.
75. Mitragotri S. Current status and future prospects of needle-free liquid jet injectors. Nature Rev 2006; 5: 543-548.
76. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Dev Rev. 2006;58:68-89.
77. Perkin FS. Jet injection of insulin in treatment of diabetes mellitus. Pric Diabetes Assoc. 1950;10:185-199.
78. Consoli A, Capani F, LaNava G, Nicolucci A, Prosperini GP, Santeusanio G, Sensi S. Administration of semisynthetic human insulin by a spray injector. Bollettino-Societa Ital Biol Sperimentale. 1984;60:1859-62.
79. Halle J, Lambert J, Lindmayer I, Menassa K, Coutu F, Moghrabi A, Legendre L, Legault C, Lalumiere G. Twice daily mixed regular and NPH insulin injections with a new jet injector versus conventional syringes: pharmacokinetics of insulin absorption. Diabetes Care. 1986; 9:279-82.
80. Verhagen A, Ebels JT, Dogterom AA, Jonkman JH. Pharmacokinetics and pharmacodynamics of a single dose of recombinant human growth hormone after subcutaneous administration by jet injection: comparison with conventional needleinjection. Eur J Clin Pharmacol. 1995;49:69-72.
81. Peter DJ, Scott JP, Watkins Frasure HE. Subcutaneous lidocaine delivered by jet injector for pain control before IV catheterization in the ED: the patients' perception and preference. Am J Emerg Med. 2002;20:562-66.
82. Benedek K, Walker E, Doshier LA, Stout R. Studies on the use of needle-free injection device on proteins. J. Chromat A. 2005;1079:397-407.
83. Garland M, Morrow DIJ, Donnelly RF, McCarron PA. A preliminary investigation into the topical delivery of pre-formed photosensitisers by jet injection. Proc of British Pharmaceutical Conference, Manchester. In: J Pharm Pharmacol. 2006;58:A16.
84. Henry S, McAllister DV, Allen MG, Prausnitz MP. Microfabricated microneedles: a novel approach to transdermal drug delivery. J Pharm Sci. 1998;87:-922-25.
85. Kaushik S, Hord AH, Denson DD, McAllister DV, Smitra S, Allen MG, Prausnitz MR. Lack of pain associated with microfabricated microneedles. Anesth Analg. 2001;92:402-504.
86. McAllister DV, Wang PM, Davis SP, Park J, Canatella PJ, Allen MG, Prausnitz MP Microfabricated microneedles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Acad Sci USA. 2003;100:13755-60.
87. Coulman SA, Barrow D, Anstey A, Gately C, Morrissey A, Wilke N, Allender C, Brain K, Birchall JC. Minimally invasive cutaneous delivery of macromolecules and plasmid DNA Via Microneedles. Curr Drug Del. 2006;3:65-75.
88. Morrow DIJ, Donnelly RF, Juzenas P, Iani V, Moan J, Morrissey A, Wilke N, McCarron PA. Microfabricated microneedles: a novel strategy for enhancing topical delivery of 5-aminolevulinic acid and preformed photosensitisers. J Pharm Pharmacol. 2006;58:A43-4.
89. Gardeniers HJGE, Luttge R, Berenschot EJW, de Boer MJ Yeshurun SY, Hefwtz M, van't Oever R, van den Berg A. Silicon micromachin.